The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial

BACKGROUND: In the OPTIMUM trial in patients with relapsing MS, treatment differences in annualized relapse rate (ARR, 0.088) and change in fatigue at week 108 (3.57 points, measured using the Fatigue Symptoms and Impacts Questionnaire–Relapsing Multiple Sclerosis, symptom domain (FSIQ-RMS-S)) favor...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Robert J, Tervonen, Tommi, Phillips-Beyer, Andrea, Sidorenko, Tatiana, Boyanova, Neli, Brooks, Anne, Hennessy, Brian, Jamieson, Carol, Levitan, Bennett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972232/
https://www.ncbi.nlm.nih.gov/pubmed/36550636
http://dx.doi.org/10.1177/13524585221140270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972232/
https://www.ncbi.nlm.nih.gov/pubmed/36550636
http://dx.doi.org/10.1177/13524585221140270

Ejemplares similares